168 / 226
Variola virus
signature (eroded specificity):
assay cross-reacts with
Cowpox virus
Exclusivity panel
Species
Strain Name
Assay 1
ct for 5 ng DNA
Assay 2
ct for 5 ng DNA
Vaccinia
Copenhagen
Negative
Negative
Vaccinia
WR
Negative
Negative
Vaccinia
ACAM2000
Negative
Negative
Vaccinia
BRZ SERRO
Negative
Negative
Cowpox
CPXV-NOR1995-MAN
Negative
Negative
Cowpox
CPXV GER1980-EP4
19
Negative
Cowpox
CPXV GER1991-3
18
Negative
Cowpox
CPXV_GER1998_2
17
Negative
Cowpox
CPXV FIN 2000
Negative
Ectromelia
ECTV Moscow
Negative
Negative
Monkeypox
MPXV RCG 2003 358
Negative
Negative
Monkeypox
MPXV USA 2003 044
Negative
Negative
Raccoonpox
RACVV71-I-84
Negative
Negative
Skunkpox
SKPV 1991
Negative
Negative
Volepox
VPXV 2004-CA-007
Negative
Negative
Camelpox
CMLV-78-I-2379
17
Negative
Taterapox (gerbilpox)
TATV-71-I-016
16
Negative
Parapoxvirus Orf
Vaccine for sheep
Negative
Negative
What we have learned about
Variola virus
diagnostic assay development/validation
Bioinformatic analysis should lead design of validation
panels
Inclusivity panel include all
Variola virus
strains with differences in
assay target region
Exclusivity panel (near neighbor
Orthopoxvirus
) contain viruses
with assay target regions most similar to
Variola virus
Exceedingly difficult to construct uniform panels for all assays due
to high similarity between
Orthopoxviruse
s
Simultaneous identification of multiple
Variola virus
signatures will increase confidence in initial identification/
verification of the pathogen with real-time PCR